Expression of histone deacetylase-1 and p300 in aristolochic acid nephropathy models

Toxicology Mechanisms and Methods

Volumn 24, Issue 6, 2014, Pages 377-384

  Tian, Yahui ^a   Yang, Yaohui ^a   Gao, Lei ^a   Zhao, Haijiao ^a   Peng, Xiaolan ^a   Zhang, Zhongwen ^a   Wu, Guojuan ^a  

^a BEIJING UNIVERSITY OF AGRICULTURE   (China)

Author keywords

Aristolochic acid I; Aristolochic acid nephropathy; HDAC1; P300; Smad7

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ARISTOLOCHIC ACID; CYTOKERATIN 18; E1A ASSOCIATED P300 PROTEIN; HISTONE DEACETYLASE 1; SMAD7 PROTEIN; ACTIN; ALPHA-SMOOTH MUSCLE ACTIN, MOUSE; ARISTOLOCHIC ACID I; EP300 PROTEIN, MOUSE; HDAC1 PROTEIN, MOUSE; MESSENGER RNA; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARISTOLOCHIC ACID NEPHROPATHY; ARTICLE; CELL CULTURE; CELL DAMAGE; CELL DIFFERENTIATION; CELL ORGANELLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; EPITHELIUM CELL; HISTONE ACETYLATION; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; ANIMAL; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GERMFREE ANIMAL; KIDNEY; METABOLISM; PATHOLOGY; ULTRASTRUCTURE;

ACTINS; ANIMALS; ARISTOLOCHIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; E1A-ASSOCIATED P300 PROTEIN; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE 1; KIDNEY; KIDNEY DISEASES; MICE; RNA, MESSENGER; SMAD PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84906244188     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2014.920448     Document Type: Article

References (43)

1. Anitua E, Sanchez M, Nurden AT, et al. (2007). Reciprocal actions of platelet-secreted TGF-beta on the production of VEGF and HGF by human tendon cells. Plast Reconstr Surg 119:950-9.
2. Chen HB, Rud JG, Lin K, et al. (2005). Nuclear targeting of transforming growth factor-beta-activated Smad complexes. J Biol Chem 280: 21329-36.
3. Cheng SK, Olale F, Bennett JT, et al. (2003). EGF-CFC proteins are essential coreceptors for the TGF-beta signals Vgl and GDF1. Genes Dev 17:31-6.
4. Chen HY, Huang XR, Wang W, et al. (2011). The protective role of Smad7 in diabetic kidney disease. Mech Therap Potential 60:590-601.
5. Chen W, Kirkbride KC, How T, et al. (2003). Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling. Science 301:1394-7.
6. Chung AC, Huang XR, Meng X, Lan HY. (2010). miR-192 mediates TGF-b/Smad3-driven renal fibrosis. J Am Soc Nephrol 21:1317-25.
7. Debelle FD, Vanherweghem JL, Nortier JL. (2008). Aristolochic acid nephropathy: A worldwide problem. Kidney Int 74:158-69.
8. Di Guglielmo GM, Le Roy C, Goodfellow AF, et al. (2003). Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol 5:410-21.
9. Dong C, Zhu S, Wang T, et al. (2002). Deficient Smad7 expression: A putative molecular defect in scleroderma. Proc Natl Acad Sci USA 99:3908-13.
10. Felici A, Wurthner JU, Parks WT, et al. (2003). TLP, a novel modulator of TGF-beta signaling, has opposite effects on Smad2-and Smad3-dependent signaling. EMBO J 22:4465-77.
11. Glasgow E, Mishra L. (2008). Transforming growth factor-b signaling and ubiquitinators in cancer. Endocr Relat Cancer 15:59-72.
12. Grönroos E, Hellman U, Heldin CH, et al. (2002). Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell 10:483-93.
13. Halkidou K, Gaughan L, Cook S, et al. (2004). Upregulation and nuclear recruitment of HDACl in hormone refractory prostate cancer. Prostate 59:177-89.
14. He S, Liu X, Yang Y, et al. (2010). Mechanisms of transforming growth factor beta(1)/Smad signaling mediated by mitogen-activated protein kinase pathways in keloid fibroblasts. Br J Dermatol 162:538-46.
15. Itoh S, ten Dijke P. (2007). Negative regulation of TGF-b receptor/Smad signal transduction. Curr Opin Cell Biol 19:176-84.
16. Izzi L, Attisano L. (2004). Regulation of the TGFb signaling pathway by ubiquitin-mediated degradation. Oncogene 23:2071-8.
17. Izzi L, Attisano L. (2006). Ubiquitin-dependent regulation of TGFb signaling in cancer. Neoplasia 8:677-88.
18. Jones PA, Martienssen R. (2005). A blueprint for a Human Epigenome Project: The AACR Human Epigenome Workshop. Cancer Res 65: 11241-6.
19. Ka SM, Huang XR, Lan HY, et al. (2007). Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice. J Am Soc Nephrol 18:1777-88.
20. Kretzschmar M, Massague J. (1999). SMADs: Mediators to the nucleus. Microbes Infect 1:1265-73.
21. Kurisaki A, Kose S, Yoneda Y, et al. (2001). Transforming growth factor-beta induces nuclear import of Smad3 in an importin-beital and Ran-dependent manner. Mol Biol Cell 12:1079-91.
22. Lan HY. (2011). Diverse roles of TGF-b/Smads in renal fibrosis and inflammation. Int J Boil Sci 7:1056-67.
23. Li JH, Zhu HJ, Huang XR, et al. (2002). Smad7 inhibits fibrotic effect of TGF-b on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 13:1464-72.
24. Li J, Zhang Z, Wu G, et al. (2009). TGF-beta 1/Smads signaling stimulates renal interstitial fibrosis in experimental AAN. J Recept Signal Transduct Res 29:280-5.
25. Lönn P, Morén A, Raja E, et al. (2009). Regulating the stability of TGFb receptors and Smads. Cell Res 19:21-35.
26. Marks P, Rifkind RA, Richon VM, et al. (2001). Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1:194-202.
27. Marumo T, Hishikawa K, Yoshikawa M, et al. (2009). Histone deacetylase modulates the pro-inflammatory and fibrotic changes in tubuloin-terstitial injury. Am J Physiol Renal Physiol 10:363-6127.
28. Monteleone G, Del Vecchio Blanco G, Monteleone I, et al. (2005). Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease. Gastroenterology 129:1420-9.
29. Miyazono K. (2009). Transforming growth factor-beta signaling in epithelial mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci 85:314-23.
30. Peng SB, Yan L, Xia X, et al. (2005). Kinetic characterization of novel pyrazole TGF-b receptor I kinase inhibitors and their blockade of the epithelia mesenchymal transition. Biochemistry 44: 2293-304.
31. TGF-beta signaling from receptors to the nucleus
32. Roberts AB. (1999). TGF-beta signaling from receptors to the nucleus. Microbes Infect 1:1265-1273. Savary K, Moustakas A. (2011). Role of TGF-b signaling in EMT, cancer progression and metastasis. Drug Discov Today 8:121-6.
33. Shi Y, Massague J. (2003). Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685-700.
34. Shi Y. (2001). Structural insights on Smad function in TGF-b signaling. Bioessays 23:223-32.
35. Simonsson M, Heldin CH, Ericsson J, et al. (2005). The balance between acetylation and deacetylation controls Smad7 stability. J Biol Chem 280:21797-803.
36. Stenvers KL, Tursky ML, Harder KW, et al. (2003). Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type receptor-deficient embryos. Mol Cell Biol 23:4371-85.
37. Verreccchia F, Mauviel A, Farge D. (2006). Transforming growth factorbeta signaling through the Smad proteins: Role in systemic sclerosis. Autoimmun Rev 5:563-9.
38. Wang Y, Zhang Z, Wu G, et al. (2008). TGF-beta 1/Smad7 signaling stimulates renal tubulointerstitial fibrosis induced by AA. J Recept Signal Transduct Res 28:413-28.
39. Wicks SJ, Crocott T, Haros K, et al. (2006). Reversible ubiquitination regulates the Smad/TGF-beta signalling pathway. Biochem Soc Trans 34:761-3.
40. Wilson AJ, Byun DS, Popova N, et al. (2006). Histone deaeetylase3(HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281:13548-58.
41. Xu L. (2006). Regulation of Smad activities. Biochim Biophys Acta 1759:503-13.
42. Yuan Q, Wang L, Zhang F, et al. (2011). Fluorofenidone suppresses epithelial-mesenchymal transition and the expression of connective tissue growth factor via inhibiting TGF-beta/Smads signaling in human proximal tubular epithelial cells. Pharmazie 66:961-7.
43. Zhou L, Fu P, Huang XR, et al. (2010). Mechanism of chronic aristolochic acid nephropathy: Role of Smad3. Am J Physiol Renal Physiol 298:F1006-17.